{"id":"rtg","safety":{"commonSideEffects":[{"rate":null,"effect":"Local inflammatory response"},{"rate":null,"effect":"Allergic reaction"}]},"_chembl":{"chemblId":"CHEMBL5174234","moleculeType":null,"molecularWeight":"341.39"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tissue transglutaminase (TG) catalyzes the formation of covalent cross-links between proteins by creating isopeptide bonds, which strengthens tissue structure and promotes hemostasis. The recombinant form (rTG) is derived from human sources and applied topically or locally to enhance wound closure, tissue adhesion, and hemostatic control in surgical and traumatic settings.","oneSentence":"rTG is a recombinant human tissue transglutaminase used as a therapeutic enzyme to cross-link and stabilize proteins in wound healing and tissue repair applications.","_ai_confidence":"low"},"_scrapedAt":"2026-03-27T23:37:22.348Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hemostasis and wound healing in surgical applications"},{"name":"Topical tissue adhesion and repair"}]},"trialDetails":[{"nctId":"NCT07241377","phase":"PHASE3","title":"A Study in Healthy Adults to Compare the Bioavailability of EPA + DHA From Two Microalgal Sources to One Fish Source and Placebo","status":"RECRUITING","sponsor":"RDC Clinical Pty Ltd","startDate":"2025-10-27","conditions":"Absorption of Omega-3, Omega-3 Supplementation, Healthy Participants","enrollment":120},{"nctId":"NCT05886582","phase":"PHASE2","title":"Transdermal Rotigotine as Adjunct to Behavioral Therapy for Cocaine Use Disorder","status":"RECRUITING","sponsor":"Virginia Commonwealth University","startDate":"2023-09-11","conditions":"Substance-Related Disorders","enrollment":40},{"nctId":"NCT06941168","phase":"","title":"Potential Advantages of Robotic Total Gastrectomy in Advanced Middle-Upper Gastric Cancer: A Multicenter Propensity Score Matching Analysis","status":"COMPLETED","sponsor":"Fujian Medical University","startDate":"2015-01","conditions":"Advanced Gastric Cancer","enrollment":1099},{"nctId":"NCT04912856","phase":"PHASE3","title":"An Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-DEE","status":"TERMINATED","sponsor":"Xenon Pharmaceuticals Inc.","startDate":"2021-08-17","conditions":"Epilepsy, Epilepsy in Children, Epilepsy; Seizure","enrollment":8},{"nctId":"NCT06241716","phase":"NA","title":"Ultrasound-assisted Versus Real-time Ultrasound-guided Combined Spinal-epidural Anesthesia in Elderly Patients","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2024-02-20","conditions":"Ultrasound Therapy; Complications","enrollment":96},{"nctId":"NCT04937452","phase":"PHASE2","title":"Dopaminergic Therapy for Frontotemporal Dementia Patients","status":"COMPLETED","sponsor":"I.R.C.C.S. Fondazione Santa Lucia","startDate":"2021-06-03","conditions":"Frontotemporal Dementia, Dementia, Aphasia, Primary Progressive","enrollment":75},{"nctId":"NCT06191445","phase":"NA","title":"Comparison of the Efficacy of Conventional Landmark, Ultrasound-Assisted, and Real-Time Ultrasound-Guided Techniques in Spinal Anesthesia for Obese Patients","status":"NOT_YET_RECRUITING","sponsor":"Uludag University","startDate":"2024-11-15","conditions":"Spinal Anesthesia, Ultrasound","enrollment":126},{"nctId":"NCT04639310","phase":"PHASE3","title":"XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy","status":"TERMINATED","sponsor":"Xenon Pharmaceuticals Inc.","startDate":"2021-03-29","conditions":"Epilepsy, Epilepsy in Children, Epilepsy; Seizure","enrollment":8},{"nctId":"NCT05735535","phase":"PHASE3","title":"Women in Dual With Dolutegravir","status":"UNKNOWN","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2023-10-01","conditions":"HIV Infections","enrollment":290},{"nctId":"NCT05694117","phase":"NA","title":"A Study of the Intervention Effect of a Hybrid Exercise Program on Elderly With Sarcopenia","status":"COMPLETED","sponsor":"Northeast Normal University","startDate":"2019-03-20","conditions":"Sarcopenia","enrollment":392},{"nctId":"NCT02464553","phase":"NA","title":"EuroPainClinics® Study I (Prospective Trial)","status":"TERMINATED","sponsor":"EPC Education s.r.o.","startDate":"2015-05-01","conditions":"Lumbar Spinal Stenosis","enrollment":20},{"nctId":"NCT01721317","phase":"PHASE4","title":"Dose-Optimization, Adjunctive Treatment Study of Ezogabine/Retigabine Immediate Release in Partial-onset Seizures","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2012-12-19","conditions":"Seizures","enrollment":6},{"nctId":"NCT01607346","phase":"PHASE4","title":"An Open Label Study to Evaluate the Effects of Ezogabine/Retigabine Added to Existing Anti-epileptic Drug(s) on Urinary Voiding Function in Subjects With Partial Onset Seizures","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2013-03-27","conditions":"Epilepsy","enrollment":10},{"nctId":"NCT01494584","phase":"PHASE2","title":"Study in Pediatric Subjects With Epilepsy","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2012-07-25","conditions":"Epilepsy","enrollment":5},{"nctId":"NCT01668654","phase":"PHASE3","title":"Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects (>= 12 Years Old) With POS or LGS","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2012-09-04","conditions":"Epilepsy","enrollment":4},{"nctId":"NCT03043560","phase":"PHASE2","title":"Study to Treat Major Depressive Disorder With a New Medication","status":"COMPLETED","sponsor":"James Murrough","startDate":"2017-09-25","conditions":"Depressive Disorder, Anhedonia","enrollment":45},{"nctId":"NCT00310375","phase":"PHASE3","title":"Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-05-01","conditions":"Epilepsy","enrollment":181},{"nctId":"NCT04411615","phase":"NA","title":"Effect of Re-esterified Triglyceride (rTG) Form Omega-3 Supplements on Dry Eye Following Cataract Surgery","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2020-07-01","conditions":"Dry Eye","enrollment":30},{"nctId":"NCT01336621","phase":"PHASE3","title":"Long-Term Safety Study of Retigabine Immediate Release (IR) as Adjunctive Therapy in the Treatment of Adults With Partial-Onset Seizures (POS)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-02-21","conditions":"Epilepsy","enrollment":98},{"nctId":"NCT01777139","phase":"PHASE3","title":"A Long-term, Safety, Tolerability, and Efficacy Study of Retigabine Immediate-release (IR) in Asian Adults With Partial Onset Seizures","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-04-11","conditions":"Epilepsy","enrollment":30},{"nctId":"NCT02450552","phase":"PHASE2","title":"Clinical Trial of Ezogabine (Retigabine) in ALS Subjects","status":"COMPLETED","sponsor":"Brian Wainger","startDate":"2015-06","conditions":"Amyotrophic Lateral Sclerosis","enrollment":65},{"nctId":"NCT02149836","phase":"PHASE2","title":"Study to Treat Major Depressive Disorder (MDD) With a New Medication","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2014-08","conditions":"Major Depressive Disorder, Depression","enrollment":18},{"nctId":"NCT00310388","phase":"PHASE3","title":"Open-Label Extension Study of the Phase 3 VRX-RET-E22-302 Double-Blind Trial. 115097","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2006-07-05","conditions":"Epilepsy","enrollment":376},{"nctId":"NCT01691872","phase":"PHASE1","title":"Pharmacokinetic Study of Retigabine Extended Release (XR) Formulation in Healthy Adult Japanese and Caucasian Subjects","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2012-10-10","conditions":"Epilepsy, Partial","enrollment":""},{"nctId":"NCT01648101","phase":"PHASE3","title":"Assessment of the Efficacy and Safety of 2 Doses of Retigabine Immediate Release (900 mg/Day and 600 mg/Day) Used as Adjunctive Therapy in Adult Asian Subjects With Drug-resistant Partial-onset Seizures","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2012-08-29","conditions":"Epilepsy","enrollment":76},{"nctId":"NCT01332513","phase":"PHASE1","title":"An Open Label, Randomised, Repeat Dose Study to Assess the Pharmacokinetic Performance of Five Ezogabine/Retigabine Modified Release (MR) Formulations at Steady State Compared to the Immediate Release (IR) Formulation.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-02-10","conditions":"Epilepsy","enrollment":36},{"nctId":"NCT01480609","phase":"PHASE1","title":"Effect of Haemodialysis on the Pharmacokinetics of Ezogabine/Retigabine and Its N-acetyl Metabolite","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-11-30","conditions":"Epilepsy","enrollment":8},{"nctId":"NCT01583036","phase":"PHASE1","title":"An Open-label, Single-centre Study Evaluating the Pharmacokinetics of Digoxin Alone and When Administered at Various Doses of Ezogabine/Retigabine in Healthy Adults. The Pharmacokinetics of Ezogabine/Retigabine and the N-acetyl Metabolite of Ezogabine/Retigabine (NAMR) Will Also be Assessed","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-01-16","conditions":"Epilepsy","enrollment":30},{"nctId":"NCT01462669","phase":"PHASE1","title":"Crossover Study to Evaluate the Pharmacokinetics of Ezogabine/Retigabine in Taiwanese Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-04-10","conditions":"Epilepsy","enrollment":1},{"nctId":"NCT00612105","phase":"PHASE2","title":"Safety/Efficacy Study of Retigabine vs. Placebo in Post-Herpetic Neuralgia (PHN)","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2007-10","conditions":"Postherpetic Neuralgia","enrollment":187},{"nctId":"NCT02727101","phase":"PHASE4","title":"Perampanel for Treatment of Adults With Refractory Focal Epilepsy : a Pilot Study.","status":"TERMINATED","sponsor":"Mid-Atlantic Epilepsy and Sleep Center, LLC","startDate":"2015-11","conditions":"Epilepsy","enrollment":8},{"nctId":"NCT02674269","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Study of Intravesical Instillations of BotuGelTM, Slow Release RTGel Based Botox® Formulations, in Idiopathic OAB Patients With Urinary Incontinence (\"INTIMO2\")","status":"WITHDRAWN","sponsor":"UroGen Pharma Ltd.","startDate":"2016-10","conditions":"Overactive Bladder","enrollment":""},{"nctId":"NCT00235755","phase":"PHASE3","title":"Retigabine Efficacy and Safety Trial for Partial Onset Refractory Seizures in Epilepsy","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-12","conditions":"Seizures","enrollment":539},{"nctId":"NCT00232596","phase":"PHASE3","title":"Retigabine (Adjunctive Therapy) Efficacy and Safety Study for Partial Onset Refractory Seizures in Epilepsy","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-09","conditions":"Seizures","enrollment":306},{"nctId":"NCT01462656","phase":"","title":"Risk of Urinary Retention With Retigabine","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2011-02","conditions":"Epilepsy","enrollment":1},{"nctId":"NCT00802074","phase":"NA","title":"An Interaction Study to Assess Drug Levels in Fasting Healthy Adult Subjects","status":"COMPLETED","sponsor":"Garden State Infectious Disease Associates, PA","startDate":"2008-12","conditions":"Healthy","enrollment":45},{"nctId":"NCT00614991","phase":"NA","title":"An Interaction Study to Assess Drug Levels in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Garden State Infectious Disease Associates, PA","startDate":"2008-01","conditions":"Healthy","enrollment":44},{"nctId":"NCT01721213","phase":"","title":"Trobalt™ Products Risk Survey","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-09","conditions":"Epilepsy","enrollment":1},{"nctId":"NCT01823159","phase":"PHASE3","title":"Cortical Excitability Changes Induced by Retigabine: a Transcranial Magnetic Stimulation Study","status":"COMPLETED","sponsor":"University Hospital of Mont-Godinne","startDate":"2013-04","conditions":"Epilepsy","enrollment":15},{"nctId":"NCT01227902","phase":"PHASE3","title":"Study of Retigabine Immediate Release as Adjunctive Therapy to Specified Monotherapy Antiepileptic Treatments in Adults With Partial-Onset Seizures","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-07","conditions":"Epilepsy","enrollment":203},{"nctId":"NCT01938560","phase":"","title":"REMS Retigabine Study","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-02","conditions":"Epilepsy","enrollment":1},{"nctId":"NCT01587339","phase":"","title":"Systematic Review: Retigabine for Adjunctive Therapy in Partial Epilepsy","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-09","conditions":"Epilepsy","enrollment":6498},{"nctId":"NCT01457989","phase":"","title":"Meta-Analysis Plan for Pooled Data for Studies VRX-RET-E22-303 and VRX-RET-E22-304","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-08","conditions":"Epilepsy, Partial","enrollment":1},{"nctId":"NCT01214278","phase":"PHASE4","title":"Bioavailability of Different n-3 Fatty Acid Formulations","status":"COMPLETED","sponsor":"Gottfried Wilhelm Leibniz Universität Hannover","startDate":"2010-10","conditions":"Health","enrollment":12},{"nctId":"NCT00740064","phase":"PHASE4","title":"Pilot Study With Isentress (Raltegravir) and Epzicom (Abacavir/Lamivudine) in Treatment Naive HIV-Infected Subjects","status":"UNKNOWN","sponsor":"Denver Infectious Disease Consultants, PLLC","startDate":"2008-05","conditions":"HIV Infections","enrollment":30}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"STATUS EPILEPTICUS"}],"_approvalHistory":[],"publicationCount":961,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["re-esterified triglycerides"],"phase":"marketed","status":"active","brandName":"rTG","genericName":"rTG","companyName":"Gottfried Wilhelm Leibniz Universität Hannover","companyId":"gottfried-wilhelm-leibniz-universit-t-hannover","modality":"Small molecule","firstApprovalDate":"","aiSummary":"rTG is a recombinant human tissue transglutaminase used as a therapeutic enzyme to cross-link and stabilize proteins in wound healing and tissue repair applications. Used for Hemostasis and wound healing in surgical applications, Topical tissue adhesion and repair.","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}